Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Phase 3 Recruiting 261 enrolled Beijing Shenogen Biomedical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to evaluate the efficacy and safety of icaritin versus huachansu in the first-line treatment of unresectable hepatocellular carcinoma with poor conditions and biomarker enrichment.

Timeline

Start: 2022-12-12
Primary completion: 2025-08-30
Completion: 2025-08-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Huachansu	Traditional medicine (herbal / TCM)	1200 mg	Oral
Subject	Icaritin	Small molecule	600 mg	Oral

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Summary

Timeline

Drugs

Indications